bovnews5h
What’s Causing Vuzix Corp (VUZI) Stock’s 214.13% Jump Over the Last Six Months?
Vuzix Corp (VUZI) stock saw a modest uptick, ending the day at $4.22 which represents a slight increase of $0.11 or 2.68% from the prior close of $4.11. The stock opened at $4.08 and touched a low of ...
Hosted on MSN12h
BTIG Downgrades Palo Alto Networks (PANW)
Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Palo Alto Networks (NasdaqGS:PANW) from Buy to Neutral. Analyst Price Forecast Suggests 22.11% Upside As of December 23, 2024, ...
Frontline plc (NYSE:FRO) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Shares of Frontline plc (NYSE:FRO – Get Free Report) have been assigned an average rating of “Moderate Buy” from the six ...
bovnews2d
BTIG Research Just Downgraded Fiverr International Ltd (FVRR) Stock—What Does This Mean for Investors?
BTIG Research has recently reduced Fiverr International Ltd (FVRR) stock to Neutral rating, as announced on November 4, 2024, according to Finviz. Earlier, on July 2, 2024, UBS had reduced the stock ...
BTIG Sticks to Their Buy Rating for Stryker (SYK)
BTIG analyst Ryan Zimmerman maintained a Buy rating on Stryker (SYK – Research Report) yesterday and set a price target of $394.00. The ...
Staar Surgical price target lowered to $39 from $49 at BTIG
BTIG lowered the firm’s price target on Staar Surgical (STAA) to $39 from $49 and keeps a Buy rating on the shares as part of ...
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives $4.94 Average PT from Analysts
Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) has earned an average recommendation of “Hold” from the seven ...
Energy stocks take ‘early lead’ in 2025 as natural gas shines
“In 2025, the energy sector will be less about barrels of oil and more about...billions of cubic feet of natural gas demand in 2025 and beyond as the technology sector intersects with the energy ...
Denali Therapeutics price target lowered to $32 from $35 at BTIG
BTIG analyst Thomas Shrader lowered the firm’s price target on Denali Therapeutics (DNLI) to $32 from $35 and keeps a Buy rating on the shares after the company announced topline data from the Phase 2 ...
Stock rally faces resistance: BTIG's Krinsky
The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...
24/7 Wall St. on MSN2d
Large-Cap Value Stocks Could Rule in 2025: 4 High-Yield Dividend Winners
According to BTIG Research, value stocks are closing at a 40-year low relative to growth. The primary reason is that ...